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Abstract
Objective: To evaluate the efficacy and safety of clozapine for treatment‐resistant bipolar disorder
(TRBD).
Methods:

A systematic review of randomized controlled studies, open‐label perspective and

retrospective studies. Samples were patients with TRBD. Interventions included clozapine
monotherapy or clozapine combined with other medications. Outcome measures were efficacy

r
Fo

and adverse drug reactions (ADRs)

Results: Fifteen clinical trials including a total of 1044 patients met the inclusion criteria. Clozapine
monotherapy or clozapine combined with other treatments for TRBD were associated with

Re

improvement in: 1) symptoms of mania, depression, rapid cycling and psychotic symptoms, with
many TRBD patients achieving a remission or response; 2) the number and duration of

vi

hospitalizations, the number of psychotropic co‐medications and hospital visits due to somatic

ew

reasons for intentional self‐harm/overdose; 3) suicidal ideation and aggressive behavior; and 4)
social functioning. In addition, patients with TRBD showed greater clinical improvement in
long‐term follow‐up when compared with published schizophrenia data. Sedation (12%),

On

constipation (5.0%), sialorrhea (5.2%), weight gain (4%), and body ache/pain (2%) were the
commonly reported ADRs; usually not requiring drug discontinuation. The percentage of severe

ly

ADRs reported, such as leukopenia (2%), agranulocytosis (0.3%), and seizure (0.5%) appeared to
be lower than those reported in published schizophrenia literature.

Conclusion: The limited current evidence supports the concept that clozapine may be both an
effective and relatively safe medication for TRBD.
Key words: clozapine, treatment‐resistant, bipolar disorder

Bipolar Disorders

Page 4 of 38
3

Introduction
Clozapine, an atypical antipsychotic, is primarily used for the treatment of
treatment‐resistant schizophrenia in most parts of the world (1, 2). Long‐term use of clozapine is
associated with improvement in clinical symptoms, measurable social and functional gains, and
decreased hospitalization as compared with typical antipsychotic agents (3, 4). Furthermore,
meta‐analyses of randomized clinical trials (RCTs) (5, 6) and a recent review of effectiveness trials
(7) supported the greater efficacy of clozapine among antipsychotics in schizophrenia.

r
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A growing number of reports, however, suggest that clozapine may also have a role in other
treatment‐resistant psychotic conditions (8‐10), such as schizoaffective disorder (SAD) and

Re

psychotic mood disorders (11‐13). Furthermore, case reports and retrospective studies suggest
that clozapine may be particularly effective in the treatment of medication‐resistant unipolar

schizophrenia (12, 14‐16).

ew

vi

depression and bipolar disorder; some even suggested it is more effective than it is for

Compared with unipolar depression, bipolar disorder (BD) is a more serious type of mood
disorder. BD is a recurrent, potentially disabling, sometimes even fatal psychiatric illness (17‐19),

On

and the estimated lifetime prevalence of various types of BD is over 2.0% (20, 21). BD is often
associated with high levels of unfavorable outcomes or treatment‐resistance (22‐24). In contrast

ly

to schizophrenia, definitions of TRBD vary greatly (17, 25‐27). However, a failure to respond to at
least two trials of dissimilar treatments, involving an adequate dose and duration, could serve as a
conservative definition (28‐31).
Although mood disorder (MD) was traditionally considered as a rather rare condition in
China, recently‐conducted epidemiological studies in the country showed that it is one of the
common mental disorders (32, 33), with a 1‐month prevalence of 6.1% (32). Unlike other
countries, clozapine has been widely used for BD in China despite not having been approved for
mood disorders (34‐36), and it is indeed one of the most commonly used antipsychotics in the
treatment of BD (34, 37, 38). Some psychiatrists even preferred it as a first‐line treatment for
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mania (38‐40). Similar to findings from studies in Western countries, RCTs showed that clozapine
was an effective add‐on treatment to antidepressants for treatment‐resistant depression (41).
Clozapine was also effective for treatment‐resistant mania in a case report (42) and a RCT (43).
Clozapine is a drug of choice for TRBD in China but the evidence for its use in Western
countries remains sparse, and the studies are limited to case reports (44), open‐label trials (11),
and only one RCT with fewer than 20 patients in each group (45). As China has the largest
population on clozapine (46‐48), the Chinese experience and studies may be of keen interest to

r
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Western psychiatrists (49). So far, no exhaustive systematic review on clozapine for TRBD has
been published.

Re

The primary aim of this review was to evaluate the efficacy and safety of clozapine for TRBD.
As previously mentioned, in addition to international databases, we also included Chinese

vi

databases that are not usually reviewed in articles written by Western psychiatrists. Particular
attention was paid to safety and tolerability, as the potentially severe adverse drug reactions

ew

(ADRs) associated with clozapine are commonly a factor discouraging clinicians from prescribing it.
Methods

On

Before we conducted this systematic review, our protocol of reviewing clozapine use for
TRBD was published online (http://www.crd.york.ac.uk/prospero/); the registration number was

ly

CRD42013004322 at the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses
(PRISMA). PRISMA provides an evidence‐based minimum set of items for reporting in systematic
reviews and meta‐analyses (50).
Types of studies
All types of trials evaluating the efficacy and safety of clozapine for TRBD were eligible for
inclusion. We included RCTs (Table 1), open‐label retrospective studies (Table 2) and prospective
trials (Table 3). We excluded meta‐analyses and systematic reviews. We also excluded from the
comprehensive review the case series and reports since they offer lower level of evidence, and
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high suspicion of publication biases. However, we included them in Table 4 and provided a brief
statement on them for the sake of entirety. The retrospective open study by Nielsen et al. (51)
was included in this review (Table 2), although the sample also included patients with non‐TRBD; it
was not possible to exclude them. All tables provided details of the contamination of the studies
by other diagnoses when it was not possible to separate the patients.
Study selection

r
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We searched PubMed, Embase, and Cochrane Library databases and the Cochrane
Controlled Trials Register of clozapine for TRBD. We also searched the Chinese databases (CBM
and CNKI databases) using the same key words. The search included all studies published between

Re

January 1979 and June 2014, regardless of language. The keywords used for the searches included:
clozapine, bipolar disorder, manic, depression, resistant/resistance/refractory, drug therapy, and

vi

trial. The keywords were used in combination with the Boolean operators AND, OR, and NOT. We
supplemented the search by using the “related article” function. We also manually searched

ew

bibliographies of RCTs, meta‐analyses, and systematic reviews for studies that were missed in the
initial electronic search (52).

On

One author (X‐BL) independently inspected citations from the searches and identified
relevant abstracts. A random 20% of the samples were independently re‐inspected by author Y‐LT

ly

to ensure reliability. When disagreements arose, the full report was acquired for more detailed
scrutiny. Full reports of the abstracts meeting the review criteria were obtained and inspected by
X‐BL. Again, a random 20% of reports were re‐inspected by Y‐LT in order to ensure reliable
selection. Where it was not possible to resolve disagreement by discussion, a third author (C‐YW)
mediated the decision. If the matter was unresolved, an attempt was made to contact the authors
of the original study for clarification (53).
Data Extraction
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Review authors X‐BL and Y‐LT considered all included studies initially, without seeing
comparison data, to judge clinical, methodological and statistical heterogeneity and thereby
decide whether each study would be included for meta‐analysis or other data synthesis. We then
extracted data into standard, simple forms. X‐BL extracted data from all included studies. In
addition, to ensure reliability, Y‐LT independently extracted data from a random sample of these
studies, comprising 30% of the total. Again, any disagreement was discussed, decisions
documented, and, if necessary, authors of studies were contacted for clarification. Data presented

r
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only in graphs and figures was extracted whenever possible, but included only if two authors
independently had the same result. We also attempted to contact authors through an open‐ended
request in order to obtain missing information or for clarification whenever deemed necessary. If

Assessment of reporting biases

vi

Re

studies were multi‐center, we extracted data relevant to each component center separately (53).

Reporting biases arise when the dissemination of research findings is influenced by the

ew

nature and direction of results. We tried to locate the research protocols of included RCTs. If the
protocol was available, outcomes in the protocol and in the published report were compared. If

compared with the actually‐reported results (54).

ly

Grading recommendations

On

the protocol was not available, outcomes listed in the methods section of the trial report were

We used the grading of recommendations assessment, development, and evaluation (GRADE)
system to rate the quality of evidence and strength of recommendations of this system review
following the guidelines of the Cochrane Collaboration. GRADE included systematic assessments of
all included trials across six main domains for each outcome: limitations of the study design and
execution, inconsistency, indirectness, and imprecision of results, publication bias, and large
treatment effect. Accordingly, we graded the recommendation for outcome measure of clozapine
for BPD as very low, low, moderate, or high (Table 5).
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Results
The various combinations of the following search “clozapine, bipolar disorder, manic,
depression, resistant or resistance, refractory” yielded 342 articles, of which 15 studies met the
criteria. In total, 1044 TRBD patients had received clozapine treatment (Figure 1). There were 2
RCTs (Table 1); 3 retrospective studies (Table 2), and 10 open‐label perspective trials (Table 3).
These studies were equally distributed across the years between 1991 and 2012, which indicates
that clozapine for TRBD has been a rather long‐ lasting, clinically important topic for the last 25

r
Fo

years.

It was not possible to conduct a meta‐analysis because of the study’s heterogeneity including

Re

differences in illness phase (mania, depression, or rapid cycling BD), methodology (open‐label trial
or RCT) and outcome definition (response or remission). Although meta‐analysis is a powerful tool

vi

for analyzing data (55), confounding inter‐study variables that cannot be controlled may violate
basic statistical assumptions, making these types of analyses error‐prone (56, 57). Therefore, we

ew

only extracted data onto standard, simple forms on a case‐by‐case basis and reported the efficacy
of clozapine for TRBD when available, as well as other descriptive statistics. Compared with

On

efficacy, there was less heterogeneity in ADRs. Therefore, we conducted data synthesis using this
term, and all trials with ADR details were included; the percentage of each ADR was computed in
this review and presented in Table 6.

ly

We were unable to locate the protocols for three RCTs; therefore, we assessed the reporting
bias by means of comparing outcomes listed in the methods with the results, which indicated that
the reported results were approximately consistent with outcomes listed in the methods.
Quality assessment of the included studies based on the GRADE approach showed many
limitations of the study designs, no obvious indirectness, imprecision in result reporting and large
treatment effect. Based on the above assessments, the quality of evidence presented for each
outcome ranged from ‘‘very low’’ to ‘‘moderate’’ (Table 5).
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Clozapine RCTs for TRBD
Our literature search yielded two clozapine RCTs for TRBD (Table 1). Among them, adjunctive
clozapine treatment was superior to treatment as usual for TRBD (45). In addition, clozapine with
added lithium was better than clozapine augmented with valproate in rapid‐cycling BD (43).
Clozapine retrospective trials for TRBD
Three clozapine retrospective trials for TRBD were identified (Table 2). Two trials described

r
Fo

the number and duration of hospitalizations, the number of psychotropic co‐medications and
hospital visits for medical reasons and for intentional self‐harm/overdose as significantly reduced
during clozapine treatment (12, 29, 51, 58). Another retrospective study comparing schizophrenia

clozapine (12).

vi

Re

and psychotic BD patients indicated that the latter had significantly higher response rates to

Clozapine open‐label prospective trials for TRBD

ew

The 10 clozapine open‐label prospective studies for TRBD (Table 3), included 5 long‐term
follow‐up studies (11, 16, 59‐61), 4 focused on mania (44, 62‐64), and another 1 focused on

On

adolescent patients (65). Studies found that patients on clozapine demonstrated a significant
decrease in the Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), Brief
Psychiatric Rating Scale (BPRS), and Clinical Global Impression Scale (CGI) scores (44, 66); the

ly

presence of suicidal ideation and aggressive behavior at intake predicted greater improvement at
endpoint (59, 65) and improvement in social functioning (16). In addition, they also found that BD
patients showed greater clinical improvement than those with schizophrenia in the long‐term
follow‐up (11, 60).
Clozapine ADRs in TRBD
ADRs were summarized in Table 6. The prevalences of the most serious ADRs were
leukopenia (2%), agranulocytosis (0.3%), and seizure (0.5%). There were no cases of myocarditis.
The most frequent clinically significant ADRs were sedation (12%), constipation (5%), sialorrhea
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(5%), weight gain (4%), and any kind of pain (2%). Other ADRs with frequency of 0.5‐1% were
dizziness, diarrhea (1%), leucopenia, transient fever, urinary incontinence, abnormal EEG,
tachycardia, orthostatic hypertension, and nausea. Other ADRs are described in Table 6.
Discussion
This is the first systematic review of clozapine for TRBD summarizing its efficacy and safety.
Our comprehensive systematic review includes 15 studies with a total of 1,044 patients and

r
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suggested that clozapine may be an effective therapy, safe and well tolerated. Although we
excluded all of the case series and case reports in this comprehensive review, the literature search
provided 13 case reports/series using clozapine for TRBD (Table 4). The 13 articles included 5 on

Re

mania (42, 70‐73) , 5 on rapid cycling BD (15, 74‐77) and 3 on other TRBDs (29, 78, 79). Overall,
almost all cases were treatment‐resistant and had a remission after switching to clozapine

ew

Strength of the study

vi

monotherapy or adding clozapine to other drugs.

While many patients with BD respond well to conventional medications (including
antidepressants, mood stabilizers and antipsychotics), a substantial proportion do not reach

On

satisfactory response (67‐69). This systematic review showed that clozapine may be an efficacious
therapy for TRBD. First, RCTs showed that: (a) clozapine add‐on treatment was superior to

ly

treatment as usual in mania, and (b) clozapine plus lithium was better than clozapine plus
valproate in rapid cycling BD. Second, retrospective studies of clozapine for TRBD indicated that
total number and duration of hospitalizations and the number of psychotropic co‐medications
were significantly reduced during clozapine treatment. Third, in open‐label perspective studies,
patients with clozapine demonstrated a significant decrease in the YMRS, HDRS, BPRS, and CGI
scores, evidenced improvement in social functioning and suicidal ideation and aggressive behavior,
and had fewer subsequent affective episodes; furthermore, TRBD patients showed greater clinical
improvement than those with schizophrenia in the long‐term follow‐up in these trials. The current
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review also suggests that clozapine may have antimanic properties in some children and
adolescents with TRBD.
In general, this review found that clozapine for TRBD was safe and well‐tolerated (Table 6).
Sedation, constipation, sialorrhea, weight gain, and pain were the common ADRs, which is
consistent with schizophrenia studies (80, 81), and they were rather mild and tolerable to most
patients. Moderate ADRs included dizziness, diarrhea, transient fever, urinary incontinence,
abnormal EEG, tachycardia, orthostatic hypertension, and nausea. Rare ADRs were sweating,

r
Fo

hyperlipidemia, diabetes type 2, influenza‐like syndrome, postprandial regurgitation, ileus, and
bradykinesia, which is also comparable with schizophrenia studies (80, 82). These ADRs were not
severe enough to result in drug discontinuation. The ADRs in the metabolic system were obviously

Re

low; there is the possibility of a major underreport in the included trials.

vi

Among all the reports, 17 patients had leukopenia (2%), 2 had agranulocytosis (0.2%), and 5
had seizures (0.5%). These figures tend to be lower than averages reported in schizophrenia

ew

reviews (83‐89). We are not sure whether the lower ADR frequency in BPD vs schizophrenia trials
is real or an artefact. Greater underreport and different methodologies may contribute to

On

artificially low ADR frequency. Some clozapine ADRs are dose‐related; others are not. Doses in
BPD trials appear lower than doses in Western schizophrenia studies, but it was not possible to
control doses for confounders such as smoking (which induced clozapine metabolism probably by

ly

inducing CYP1A2) and racial differences (see the commentary in the limitation section) (64, 87, 89).
The agranulocytosis risk is still a concern for clinicians, but mandatory blood monitoring has been
shown to considerably reduce the incidence of fully developed cases of agranulocytosis (80). Thus,
appropriate management of clozapine ADRs facilitates a maximization of the benefits of clozapine
treatment, and physicians and patients alike should be aware that there is a range of benefits to
clozapine use that outweighs its risk (80, 90, 91).
Clozapine treatment was associated with significant improvement in tardive dyskinesia in
seven patients (92‐94); clozapine may be useful for long‐term treatment to lower tardive
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dyskinesia risk (93, 95, 96). Furthermore, once tardive dyskinesia or dystonia is established,
clozapine may be useful for both control of the movement disorder and BD (93, 96).
The major strength of this study is that we also searched Chinese databases in this
systematic review, which included all TRBD clozapine trials conducted in China, where clozapine is
widely used. Thus, it is the first review to include all trials available without applying any language
restrictions. We found clozapine RCTs in monotherapy or combined with other medications versus
other treatments in TRBD patients; the comparison treatments included mood stabilizer (97, 98),

r
Fo

other antipsychotics (99‐102), clozapine plus mood stabilizer versus mood stabilizer (97, 103, 104),
clozapine plus mood stabilizer versus other antipsychotics plus mood stabilizer (103‐109) in the
treatment of BD in China. We also found 2 RCTs, 1 open‐label perspective study and 2 case reports

Re

of clozapine for TRBD in the Chinese literature, including the only placebo‐controlled clozapine
RCT for TRMD (41).

ew

vi

Limitations of the study

A few limitations of the current review need to be acknowledged. First, it was not possible to
conduct a meta‐analysis because of the study’s heterogeneity, including differences in illness

On

phase (mania, depression or rapid cycling BD), methodology (open‐label trials or RCTs) and
outcome definition (response or remission). This great heterogeneity may violate basic statistical

ly

assumptions and make these analyses error‐prone. Therefore, we only extracted data onto
standard, simple forms on a case‐by‐case basis and reported the efficacy of clozapine for TRBD
when available. Compared with data on efficacy, there was lower heterogeneity with ADR data,
therefore data synthesis using ADRs was conducted and the percentage of each ADR was
computed (Table 6).
Second, most of the clinical trials included here had major methodological problems:
although this review included 15 clinical trials, most of them were open‐label observational trials;
only 2 RCTs were available. There were no obvious reporting biases in the RCTs, but reporting
biases in other studies is possible. Furthermore, the GRADE approach showed the quality of the
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evidence was ‘‘very low’’ in CGI score and psychosocial function; other outcomes were from ‘‘low’’
to ‘‘moderate’’ (Table 5). Therefore, the current review provided limited evidence for clozapine
use. However, two strengths of this current review also need to be mentioned: (1) all available
trials were included, without applying any language restrictions; and (2) we provided certain
supporting evidence by means of reporting the efficacy case‐by‐case analysis and computing the
percentage of each ADR (Table 6).
Third, some trials were “contaminated” by some patents with a diagnosis of SAD or

r
Fo

schizophrenia; which does not correspond to the population described as the target population of
interest (TRBD). In some trials, we could not separate TRBD patients from the others but the
tables provide the details of these “contaminated” studies.

Re

A fourth limitation of this review and all the studies reviewed in it is the lack of close

vi

attention to clozapine pharmacokinetic issues on dosing. Clozapine dosing is influenced by racial
differences, drug‐drug interactions and smoking. In 1997, it was already reported that Chinese

ew

patients tend to receive approximately half of the clozapine dosage used in Western counties (110,
111) but appear to have roughly similar clozapine levels, which is indicative of lower clozapine

On

metabolism in Chinese patients. The literature has not stressed this difference nor provided an
explanation. Sirot et al. (2009) completed a very important study that has not received enough
attention in the literature (112). They described CYP2C19 poor metabolizers (PMs) as having

ly

2.3‐fold higher plasma clozapine concentrations than patients with other CYP2C19 genotypes.
Approximately 25% of the Chinese population is CYP2C19 PMs.
Studies of adjunctive clozapine treatment in TRBD usually ignore the major differences in
clozapine metabolism associated with co‐medication. Carbamazepine is a major inducer of
clozapine metabolism (113) and it is possible that valproate may be a mild inducer (114).
Fluvoxamine is a major inhibitor of clozapine metabolism (115) and paroxetine and fluoxetine are
mild inhibitors (114, 115).
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In conclusion, future studies and meta‐analysis of clozapine for TRBD will need to pay
attention to important pharmacokinetic differences associated with racial differences,
co‐medication and smoking, which may have major influences on clozapine dosing but at present
are ignored in most published articles.
Comparison with other studies
Poon et al. (2012) performed a literature review on TRBD research findings (17). It provided

r
Fo

few promising leads other than the use of clozapine for TRBD mania, which is comparable to our
analysis. Their review was limited by: 1) inclusion of only 2 clozapine trials (44, 45), 2) lack of
report on clozapine ADRs, and 3) lack of inclusion of Chinese studies which include the larger

Re

numbers of patients.

Gitlin et al. (2003) conducted a review on this topic (116). Their review indicated that

vi

combining multiple agents was the commonly used clinical strategy for TRBD; an approach that

ew

may be effective for treatment‐resistant patients included high‐dose thyroid augmentation,
clozapine, calcium channel blockers, and electroconvulsive therapy (ECT), which is consistent with
our findings. However, only 3 studies of clozapine treatment were included (45, 60, 64), and none

On

of the Chinese studies were included. Similarly, there was no safety analysis or data synthesis.
Frye et al. (1998) reviewed the use of atypical antipsychotics in the treatment of BD, focusing

ly

on clozapine as the prototypical agent (117). It indicated that the early clinical experience of
clozapine as a potential mood stabilizer suggests greater antimanic than antidepressant properties.
However, this review only included some trials conducted before 1998, which excluded most trials
of clozapine for TRBD. Similarly, there was no safety analysis or data synthesis in this analysis.
Conclusions
TRBD is a complex, often severe and disabling psychiatric disorder and it often poses a
therapeutic challenge (17, 118). This systematic review showed that clozapine monotherapy or its
combination with other medications for TRBD may be both safe and effective. Long‐term use of
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clozapine appeared to be associated with improvement in clinical symptoms, measurable social
and functional gains, and decreased hospitalization. Constipation, sedation, sialorrhea, weight
gain, aches and pain were the common reported ADRs, though none were severe enough to result
in drug discontinuation. The percentage of leukocytopenia, agranulocytosis and seizure were
lower than in studies of clozapine for schizophrenia, but it cannot be ruled out that they may be
contaminated by ADR underreport. Clozapine for TRBD may increase treatment compliance, which
may offer additional therapeutic benefits. On the other hand, some patients may have poor

r
Fo

adherence or may not be willing to start clozapine treatment due to the required blood collections
to avoid agranulocytosis.

This comprehensive review focused on TRBD but future reviews need to focus on the role of

Re

clozapine for the treatment of BD in general. Though clozapine is rarely used for
non‐treatment‐resistant BD elsewhere in the world, emerging evidence from China is encouraging

vi

(41, 97, 98). Since the early 1980s, few clozapine RCTs for BD in general have been published; once

ew

more clozapine RCTs are published, a meta‐analysis on this important topic will provide clinicians
with more choices when treating patients with all kinds of BD, including those with
non‐treatment‐resistant forms.

On
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Table 1. Clozapine RCTs for TRBD
Suppes et al. 1999 (45)
Population: Thirty‐eight patients meeting the DSM‐IV criteria for BD (n=26) or SAD (n=12) who were deemed treatment‐resistant [failure of
adequate treatment with two mood stabilizers (lithium, valproate, carbamazepine) at standard therapeutic levels]. Subjects were randomly
assigned to clozapine add‐on treatment (N = 19) or treatment as usual (no clozapine) (N = 19).
Intervention: Clozapine (355 mg/day) add‐on therapy
Comparison: Treatment as usual
Measures: Patients received monthly ratings on the BPRS, CGI, BRMS, HDRS, SAPS, SANS, AIMS, and a 40‐item side effect checklist.
Study design: Randomized, treatment as usual – controlled study followed up for 1 year.
Resultsa: Significant between‐group differences were found in scores on all rating scales except the HDRS. Total medication use over 1 year
significantly decreased in the clozapine group. No significant differences in physical complaints between groups were noted.
Tan et al. 2010 (43)
Population: 71 patients with DSM‐IV BD who were classified as TRBD were randomly assigned to clozapine added to lithium treatment (N = 35) or
clozapine added to valproate treatment (N = 36). Treatment resistance was defined as failure of adequate treatment with 2 different
antidepressants.
Intervention: Clozapine (100‐300 mg/day) added to lithium (500‐1500 mg/day)
Comparisons: Clozapine (100‐300 mg/day) added to valproate (600‐1800 mg/day)
Measures: Patients received ratings on BPRS, HDRS, and TESS at weeks 0, 1, 2, 4 and 6.
Study design: Randomized, open‐controlled study
Resultsa: In the study group, 89% of patients were responders (based on BPRS and HDRS) to clozapine added to lithium compared with 64% of
patients receiving clozapine added to valproate (p<0.05). No significant differences in ADRs between groups.
AD = antidepressant; ADR = adverse drug reaction; AIMS = Abnormal Involuntary Movement Scale; BD = bipolar disorder; BPRS = Brief Psychiatric
Rating Scale; BRMS = Bech‐Rafaelsen Mania Scale; CGI= Clinical Global Impression; DSM‐IV = Diagnostic and Statistical Manual of Mental Disorders
4th edition; ECG = electrocardiogram; GAS = Global Assessment Scale; HDRS = Hamilton Depression Rating Scale; RTC= randomized controlled trial;
SANS = Scale for the Assessment of Negative Symptoms; SAD = schizoaffective disorder; SAPS = Scale for the Assessment of Positive Symptoms; TCA=
tricyclic antidepressant; TESS = Treatment Emergent Symptom Scale; TRBD = treatment‐resistant bipolar disorder.
a
Clinical remission and response was defined differently in each study
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Table 2. Clozapine retrospective studies for TRBD
McElroy et al. 1991 (12)
Sample: All patients were either inadequately responsive to or unable to tolerate standard biological therapies.
Methods: Survey of treating clinicians and chart data for all 85 consecutive patients, including 39 with schizophrenia, 25 with SAD, and 14 with
psychotic BD, who received clozapine for at least 6 weeks at one center.
Results: Compared to patients with schizophrenia, patients with SAD and psychotic BD had significantly higher response rates to clozapine (10%
for schizophrenia vs. 15‐20% for SAD and 43% for psychotic BD, respectively).
Chang et al. 2006 (58)
Sample: TRBP to conventional treatment.
Methods: Analysis of clinical data from medical records of 51 patients with DSM‐IV BD treated with add‐on clozapine for > 6 months
Results: The number of hospital days per year was reduced in 90% of patients after clozapine add‐on treatment. Total number and duration of
hospitalizations per year also decreased. Significant reductions were found in the number and duration of hospitalizations associated with
manic, depressive, and hypomanic episodes. Long‐term efficacy of clozapine add‐on was supported by continuous decreases in hospital days
per year in the 27 selected patients.
Nielsen et al. 2012 (51)
Sample: A total of 21,473 patients with a lifetime diagnosis of ICD‐10 BD, of which only 326 (1.5%) were treated with clozapine and were
included in a mirror‐image analysis.
Methods: A pharmacy‐epidemiologic database study was carried out in Denmark, investigating the effectiveness of clozapine in BD patients
(without a schizophrenia‐spectrum disorder), between 1996 and 2007, using a two‐year mirror‐image design.
Results: Clozapine appears to be an appropriate choice for TRBD. Compared to the pre‐clozapine period, during clozapine treatment, the mean
number of bed‐days decreased from 179 to 35. The mean number of admissions was reduced from 3.2 to 2.0. Overall, 240 patients (74%) had
reduced bed‐days and 130 (40%) were not admitted while treated with clozapine. Moreover, the number of psychotropic co‐medications was
reduced from 4.5 DDD (25‐75 percentiles: 2.4‐8.2) to 3.9 DDD (25‐75 percentiles: 2.4‐6.1). The percentage of patients with hospital visits for
intentional self‐harm/overdose was reduced significantly from 8% to 3%.
ADR = adverse drug reaction; BD = bipolar disorder; BPRS = Brief Psychiatric Rating Scale; CGI= Clinical Global Impression; DDD = defined daily doses;
DSM‐IV = Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD‐10 = International Classification of Diseases, 10th edition; TRBD =
treatment‐resistant bipolar disorder.
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Table 3. Clozapine open‐label trials for TRBD
Study

Subjects

Suppes et
al. 1992
(16)

7 with
dysphoric
mania

Banov et al.
1994 (11)

52 BD, 81 SAD,
14 UD, 40 SCH

Undefined

Kimme et
al. 1994
(62)
Kowatch et
al. 1995
(66)
Zarate et al.
1995 (61)

25 manic with
BD or SAD

Li, ACs, and ≥ 2 APs, or
intolerant

CLZ

5 children or
adolescents
with BD
17 mood
disorders

Multiple trials of APs
and ACs, or intolerance

CLZ (75‐225)+Li 2

There was a 42% decrease in the CGI. Treatment was for
aggressive behavior and psychotic symptoms.

CLZ

65% (11/17) had no subsequent rehospitalization or mood
episode. Significant improvement in CGI scores.

Calabrese
et al. 1996
(44)

25 acutely
manic

Combinations of Li,
ACs, APs, and ECT; or
had tardive dyskinesia.
Li, ACs, and APs,
intolerable ADRs, or
both

Green et al.
2000 (63)

22 active manic

Ciapparelli
et al. 2000
(59)

34 psychotic
BD, 31 SCH, 26
SAD, bipolar
type
37 psychotic
BD, 34 SCH, 30
SAD, bipolar
type
9 BD

Ciapparelli
et al. 2003
(60)
Fehr et al.
2005 (64)

Resistance definition
(Failure of)
Standard treatments
including ACs

Fo

Treatments
(mg/day)
CLZ (50‐500) +
ACs
CLZ

rR

ev

Duration Main findings
(months)
36‐60
Symptomatic and functional improvement was assessed.
Most of the patients sustained substantial gains in
psychosocial function follow‐up over 3 years. No further
hospitalizations were needed in 6 of 7 patients.
18.7
BD manic and SAD bipolar had significantly better outcomes
than UD, BD, and SAD depressed patients. BD and SAD
patients had significantly greater improvement in social
functioning than SCH patients. One or more episodes of
depression prior to CLZ predicted CLZ discontinuation.
13
18 of 25 patients demonstrated a greater than 50% decrease
in the YRMS

iew

CLZ (494)

CLZ
500 mg/day of
chlorpromazine or its
equivalence and Li of at
least 6 weeks
CLZ flexible
Adequate treatment
with 3 different classes doses
of APs

16.1
4

3

24

Adequate treatment
with 3 different classes
of APs

CLZ flexible
doses

48

2 ACs + APs

CLZ(156+/‐77)

12

On

72% (18/25) improved on the YMRS and 32% (8/25) improved
on the BPRS. The BD patients as compared to SAD patients,
and the non‐rapid patients as compared to rapid cyclers, had
significantly greater improvement in total BPRS score.
57% (13/22) improved on BPRS; 57% (12/22) on YMRS; 39%
(8/22) on CGI and 77% (17/22) experienced at least a 20%
reduction on all three scales.

ly

All patients showed significant improvement 24 months from
intake (based on BPRS and CGI). The presence of suicidal
ideation at intake predicted greater improvement at
endpoint.
SAD and BD show greater clinical improvement than those
with SCH. Patients with BD have the shortest time to
response and the highest psychosocial and occupational
functioning levels (based on BPRS, CGI and GAF).
3 patients demonstrated striking mood stabilization and
returned to previous levels of functioning (based on BPRS
and HDRS); 5 patients had moderate improvement in mood
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stabilization and functioning (based on BPRS and HDRS); and
1 patient showed a minimal response.
AC = anticonvulsant; AD = antidepressant; ADRs = adverse drug reaction; AP = antipsychotic; BD = bipolar disorder; BPRS = Brief Psychiatric Rating
Scale; CGI= Clinical Global Impression; CLZ = clozapine; ECT = electroconvulsive therapy; GAF = Global Assessment of Functioning; HDRS = Hamilton
Depression Rating Scale; Li = lithium; SCH = schizophrenia; SAD = schizoaffective disorder; TRBD = treatment‐resistant bipolar disorder; UD = unipolar
depression; VPA = valproate; YMRS = Young Mania Rating Scale.
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Table 4. Clozapine case series and reports for TRBD

Subjects

Author, year

Age
gender

2 RC BD

Calabrese et
al. 1991 (74)
Suppes et al.
1994

47 yo ♀
48 yo ♀
43 yo ♀
25 yo ♀
45 yo ♀
Unavailable

3 RC BD

4 euphoric mania
2 mania
1 RC BD
3 mania
1 mania

1 mania
1 RC BD
1 juvenile‐
onset BD
3 BD, 2 UD
1 BD
1 RC BD

Antonacci et
al. 1995 (70)
Poyurovsky et
al. 1996 (71)
Lancon et al.
1996 (75)
Mahmood et
al. 1997 (72)
Chanpattana
et al. 2000
(73)
Xu et al. 2003
(42)
Chen et al.
2005 (76)
Vijay Sagar et
al. 2005 (79)
Quante et al.
2007 (74)
Gupta et al.
2009 (78)
Bastiampillai
et al. 2010
(77)

Fo
24 yo ♂
41 yo ♀
42 yo ♀

Resistance
definition
(Failure of)
AC+ AP

Treatments
(mg/day)

Duration
(months)

Main findings

CLZ (250‐350)

1.5‐3.5

Remission

AP + AC

CLZ (150‐400) + Li

12‐20

2 remission, 1 response

Standard
treatments + AC
AP + AC

CLZ

_

CLZ (250‐350) +
ECT
CLZ

_

Enhanced functioning and
insight
Remission

_

Successfully treated

CLZ

_

Successfully treated

18

Complete remission

ly
1

Remarkably effective

36

Complete remission

24

Remission
4/5 patients showed steady
improvement
No hospitalization and no more
episodes
Sustained remission

rR

Unavailable

ev

Conventional
therapy
AP + AC

iew

On

26 yo ♂

Conventional
treatment

CLZ (200) +ECT

40 yo♀

AP + AC

38 yo ♀

Various biological
therapies
AC combinations

CLZ (600) + Li
(1500) + CBZ (600)
CLZ (350) + TPR
(300)
CLZ (200)

Not
provided
28 yo ♂

Medications + ECT

CLZ (125 and 375)

12

Standard AC

CLZ (350)

66

52 yo ♀

Standard APs + ACs

CLZ (150) + LTG
(100)

60

18 yo ♀
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7 SAD and psychotic Bennedetti et 3 36yo ♂s
Treatment resistant Aripiprazole (6.8)
_
Remission
BD
al. 2010 (29)
4 40 yo ♀s
+CLZ (293)
AC = anticonvulsant; AD = antidepressant; AP = antipsychotic; BD = bipolar disorder; CBZ = carbamazepine; CLZ = clozapine; ECT = electroconvulsive
therapy; Li = lithium; LTG = lamotrigine; RC = rapid cycling; SAD = schizoaffective disorder; TCA = tricyclic antidepressant; TPR= topiramate; TRBD =
treatment‐resistant bipolar disorder; UD = unipolar depression; yo = year old.
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Table 5. GRADE Analysis: quality assessment of clozapine for TRBP.
Critical outcome
Participants
Risk of
Inconsistency
(studies)
bias
Open studies

Indirectness
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Imprecision

Public bias

Large effect Overall quality of
evidenced

No
CGI score
236(5)
Seriousa
No
No
Undetected
No
Very Low
BPRS score
248(5)
No
No
No
No
Undetected
No
Low
YMRS score
47(2)
No
No
No
No
Undetected
No
Low
b
Social functioning
No
No
No
Undetected
No
Very Low
304(4)
Serious
Hospital days per year
No
No
No
No
Undetected
No
Low
377(2)
The mean number of admissions
No
No
No
No
Undetected
No
Low
377(2)
RCTs
BPRS score
109(2)
Noc
No
No
No
Undetected
No
Moderate
c
HDRS score
109(2)
No
No
No
No
Undetected
No
Moderate
CGI= Clinical Global Impression; BPRS = Brief Psychiatric Rating Scale; HDRS = Hamilton Depression Rating Scale; RCT= Randomized clinical trial; TRBD
= treatment‐resistant bipolar disorder; YMRS = Young Mania Rating Scale.
a
Incomplete accounting of patients and outcome events.
b
Relatively few patients (n≤10).
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c

Lack of allocation concealment.

d
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The quality of evidence was rated using the GRADE Working Group system. High quality indicates that further research is very unlikely to change
our confidence in the estimate of effect but none of the studies reached that level. Moderate quality indicates that further research is likely to have
an important impact on our confidence in the estimate of effect and may change the estimate. Low quality indicates that further research is very
likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality indicates that we
are very uncertain about the estimate.
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Table 6. Clozapine ADRs in TRBD
ADRs
Blood cells

Metabolic system

Endocrine system

N (% in 797 total)
14 (1.7)

Decreases in WBC
Agranulocytosis

6 (0.8)
2 (0.3)

Weight gain
Weight loss
Hyperlipidemia
Increased appetite

31 (4.0)
1 (0.1)
1 (0.1)
1 (0.1)

Diabetes type 2

1 (0.1)

Sialorrhea
Sweating
Dry mouth
Influenza‐like syndrome

42 (5.2)
4 (0.5)
1 (0.1)
1 (0.1)

Abnormal EEG
Orthostatic hypertension

6 (0.8)
6 (0.8)

Tachycardia
Orthostatic hypotension

6 (0.8)
2 (0.2)

r
Fo

Leukopenia

Cardiovascular system

Constipation
Diarrhea
Nausea/vomiting
Postprandial regurgitation

40 (5.0)
8 (1.1)
5 (0.6)
1 (0.1)

Ileus

1 (0.1)

Urinary incontinence
Seizure
Tremors
Fatigue
Neuroleptic malignant syndrome
Bradykinesia
Enuresis
Mental confusion

15 (1.8)
11 (1.4)
7 (1.1)
8 (0.9)

ly

Body ache and pain
Dizziness
Sleep cycle inversion
Transient fever

98 (12.2)

On

Sedation

ew

Nervous system

vi

Re

Digestive system

6 (0.8)
4 (0.5)
2 (0.2)
2 (0.2)

1 (0.1)
1 (0.1)
1 (0.1)
1 (0.1)
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ADR = adverse drug reaction; EEG = electroencephalography; TRBD = treatment‐resistant bipolar
disorder; WBC = white blood cell count.
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Figure 1 PRISMA flow diagram
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